DHR

Prezzo Danaher

DHR
$178,98
-$1,64(-0,90%)

*Data last updated: 2026-04-28 22:10 (UTC+8)

As of 2026-04-28 22:10, Danaher (DHR) is priced at $178,98, with a total market cap of $127,83B, a P/E ratio of 44,80, and a dividend yield of 0,75%. Today, the stock price fluctuated between $177,35 and $183,00. The current price is 0,91% above the day's low and 2,19% below the day's high, with a trading volume of 4,41M. Over the past 52 weeks, DHR has traded between $175,00 to $242,80, and the current price is -26,28% away from the 52-week high.

DHR Key Stats

Yesterday's Close$177,25
Market Cap$127,83B
Volume4,41M
P/E Ratio44,80
Dividend Yield (TTM)0,75%
Dividend Amount$0,40
Diluted EPS (TTM)5,21
Net Income (FY)$3,61B
Revenue (FY)$24,56B
Earnings Date2026-07-28
EPS Estimate1,85
Revenue Estimate$6,09B
Shares Outstanding721,22M
Beta (1Y)0.986
Ex-Dividend Date2026-03-27
Dividend Payment Date2026-04-24

About DHR

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
SectorHealthcare
IndustryMedical - Diagnostics & Research
CEORainer Blair
HeadquartersWashington,DC,US
Official Websitehttps://www.danaher.com
Employees (FY)60,00K
Average Revenue (1Y)$409,46K
Net Income per Employee$60,23K

Danaher (DHR) FAQ

What's the stock price of Danaher (DHR) today?

x
Danaher (DHR) is currently trading at $178,98, with a 24h change of -0,90%. The 52-week trading range is $175,00–$242,80.

What are the 52-week high and low prices for Danaher (DHR)?

x

What is the price-to-earnings (P/E) ratio of Danaher (DHR)? What does it indicate?

x

What is the market cap of Danaher (DHR)?

x

What is the most recent quarterly earnings per share (EPS) for Danaher (DHR)?

x

Should you buy or sell Danaher (DHR) now?

x

What factors can affect the stock price of Danaher (DHR)?

x

How to buy Danaher (DHR) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts su Danaher (DHR)

SelfRugger

SelfRugger

04-26 07:36
Palantir upgraded, Workday downgraded: Wall Street's top analyst calls ====================================================================== Palantir upgraded, Workday downgraded: Wall Street's top analyst calls The Fly Wed, February 18, 2026 at 11:50 PM GMT+9 3 min read In this article: * StockStory Top Pick PLTR +4.80% * MOD +3.31% WDAY -0.35% NBIS +4.49% CROX -2.04% The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. **Top 5 Upgrades: ** * Mizuho upgraded **Palantir **(PLTR) to Outperform from Neutral with an unchanged price target of $195. The firm says the company is delivering total revenue growth, acceleration, and margin expansion "at scale that is unlike anything else in software." * Rosenblatt upgraded **Cadence Design** (CDNS) to Buy from Neutral with a price target of $360, up from $335. The firm views the company's Q4 results as solid "across the board." * Baird upgraded **Itron **(ITRI) to Outperform from Neutral with a price target of $128, up from $118. Baird is a buyer of the stock post the Q4 report. * Citizens upgraded **Rush Street Interactive** (RSI) to Outperform from Market Perform with a $24 price target. The firm says the company "continues to prove that it has built one of the most durable business models" in the online gaming space. * TD Cowen upgraded **Medpace **(MEDP) to Hold from Sell with a price target of $419, down from $462. The shares have re-rated from a peak multiple and now reflect fair value, the firm tells investors in a research note. **Top 5 Downgrades:** * Citizens downgraded **Workday **(WDAY) to Market Perform from Outperform without a price target after the company announced the return of its founder Aneel Bhusri as CEO and preannounced Q4 results. Bhusri may need time and investments to drive the organic AI innovation that Workday needs to successfully transition from the software-as-a-service to the AI era, the firm tells investors in a research note. * Williams Trading downgraded **Crocs **(CROX) to Sell from Hold with a price target of $84, up from $75. The firm says demand for Crocs and HeyDude "continues to erode" in the U.S. * Citizens downgraded **Similarweb **(SMWB) to Market Perform from Outperform without a price target. The company reported a big revenue miss in Q4 and its guidance is worse than expected on both the top and bottom line, the firm tells investors in a research note. * Truist downgraded **Genuine Parts** (GPC) to Hold from Buy with a price target of $127, down from $162. The company's business separation should be a positive, but its auto business continues to disappoint, the firm tells investors in a research note. * BTIG downgraded **Masimo **(MASI) to Neutral from Buy following the announcement that Danaher (DHR) entered a definitive agreement to acquire the company for $180/share in cash. **Top 5 Initiations: ** * Mizuho resumed coverage of **Medtronic **(MDT) with an Outperform rating and $125 price target. The firm says the company's new product launches can drive growth higher into fiscal 2027. * Compass Point initiated coverage of **Nebius **(NBIS) with a Buy rating and $150 price target. Nebius is a full-stack AI infrastructure company that sells GPU compute and its associated software stack through an AI cloud platform whose Russia operating footprint was sold in a divestment, leaving the company positioned today with a separate, internationally focused perimeter. * UBS initiated coverage of **AeroVironment **(AVAV) with a Neutral rating and $259 price target. UBS says its 2028 margin assumptions are 100 basis points below a "uniformly bullish" consensus. * UBS initiated coverage of **Kratos Defense** (KTOS) with a Neutral rating and $79 price target. The firm says the company's growth is priced in at current share levels. * Roth Capital initiated coverage of **Modine **(MOD) with a Buy rating and $263 price target. The company Modine has created a "unique one-stop shop" for thermal solutions used for data center cooling technologies and refrigeration, the firm tells investors in a research note. Terms and Privacy Policy Privacy Dashboard More Info
0
0
0
0